Plain-English translation of NCT05519085 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is comparing two different three-drug combinations to treat multiple myeloma that has come back or stopped responding to previous treatments. One combination uses a new medication called along with and , while the other uses with the same two drugs. Researchers want to see which combination works better and is safer for patients like you.
Multiple myeloma often returns or becomes resistant to earlier treatments, and doctors need better options to help patients. This medication is being tested because early results suggest it might be more effective than current standard treatments for people in this situation.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of the two medication combinations, taken over repeated treatment cycles. You would visit the study clinic regularly for blood tests, exams, and to receive your medications, which may be given intravenously or by mouth depending on the specific regimen. The study aims to track how well the medication works and monitor you for any side effects throughout your treatment.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States